Overview

A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Status:
Recruiting
Trial end date:
2023-03-11
Target enrollment:
Participant gender:
Summary
To select a dose and to make a decision for Phase 3 study
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Harbour BioMed (Guangzhou) Co. Ltd.